Tirzepatide (also known as GIP/GLP-1 dual agonist) is a dual GIP/GLP-1 receptor agonist approved for diabetes and weight management. This page covers what the published research does — and does not — establish about it in relation to fat loss and weight management.
Tirzepatide is researched for Weight management, Metabolic health — which is why it appears in discussions of fat loss and weight management.
Research status: FDA-approved with large-scale human clinical trials.
How Tirzepatide is thought to work
Tirzepatide is a "dual agonist" that activates both the GIP and GLP-1 receptors. Engaging two incretin pathways appears to produce strong effects on appetite, blood sugar, and body weight, and it is FDA-approved for type 2 diabetes and chronic weight management.
What it does not establish
Prescription medication with known side effects. Use only under medical supervision.
Nothing on this page is a recommendation to use Tirzepatide, and Selpho publishes no dosing, reconstitution or sourcing information. Read how we decide what goes in the library.
Other peptides researched for Fat Loss
A GLP-1 receptor agonist approved for type 2 diabetes and weight management.
An investigational triple GIP/GLP-1/glucagon agonist studied for weight loss.
A long-acting amylin analog studied for appetite and weight, often with semaglutide.
An investigational GLP-1/glucagon dual agonist studied for weight and liver health.
Frequently asked questions
FDA-approved with large-scale human clinical trials. Research relevant to this area covers weight management, metabolic health. That is a description of where the research points, not evidence that it will work for you — and Selpho does not provide dosing or medical advice.
FDA-approved with large-scale human clinical trials.
Prescription medication with known side effects. Use only under medical supervision. Always speak to a licensed healthcare professional before considering any peptide.
Type 2 diabetes and chronic weight management, supported by large clinical trials. It targets both GIP and GLP-1 receptors.
Trials have shown substantial glycemic and weight effects, but comparisons should be interpreted by a clinician for your situation. Both are prescription medications.
Is Tirzepatide right for your situation?
Describe your goals and the free Peptide Advisor will match them against the research — no signup, no sales pitch.
Ask the Advisor — freeThis page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.